18th May 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it will be presenting new positive pre-clinical data relating to its ExoPr0 CTX cell-derived exosome therapy candidate at a leading scientific conference.
11th May 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce that it has been awarded a £1.8 million grant from Innovate UK to further advance its next generation commercial cell therapy manufacturing capabilities.
5th May 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it will today be presenting new data relating to the characterisation and scale-up of its CTX cell-derived exosome therapy candidates at a leading scientific conference in London.
21st April 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides an update on its cell therapy development programmes targeting degenerative diseases of the retina.
21st April 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update on its CTX-based cell therapy development programmes.
15 February 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that its CTX cell therapy candidate has been featured in the BBC documentary, “Andrew Marr: My Brain and Me”, which was screened for the first time last night on BBC2.
07 February 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 7 February 2017 that, on the same day, Michael Hunt, the Company’s Chief Financial Officer, acquired 250,000 ordinary shares of 1p each (“Ordinary Shares”) at a price of 2.64p per share.
To watch the interview with CEO Olav Hellebo which was broadcast on CNBC on the 3oth December 2016, please click here.
In this interview, CFO Michael Hunt explains the core technology of ReNeuron’s business, the stem cell science it is developing, optimising and harnessing to create therapeutic products. He discusses the recently reported early Phase II clinical trial data for its CTX stem cell therapy in stroke and why this has given ReNeuron the confidence to commence a pivotal Phase II/III clinical trial in 2017. Finally, he also discusses expected newsflow resulting from the remainder of ReNeuron’s pipeline – critical limb ischaemia (Phase I) and hRPC or retinitis pigmentosa (Phase I/II).
For the interview please click here…
14 December 2016: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 14 December 2016 that, on the same day, Olav Hellebø, the Company’s Chief Executive Officer, acquired 346,644 ordinary shares of 1p each (“Ordinary Shares”) at a price of 2.8848p per share.
